Carter Gould
Stock Analyst at Cantor Fitzgerald
(3.30)
# 972
Out of 4,944 analysts
206
Total ratings
48.36%
Success rate
1.63%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $485 | $395.92 | +22.50% | 4 | Aug 5, 2025 | |
| AMGN Amgen | Reiterates: Neutral | $305 | $289.33 | +5.42% | 17 | Jun 24, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Neutral | $55 | $47.85 | +14.94% | 16 | Apr 23, 2025 | |
| REGN Regeneron Pharmaceuticals | Assumes: Overweight | $695 | $561.55 | +23.76% | 20 | Apr 22, 2025 | |
| PFE Pfizer | Initiates: Neutral | $24 | $25.16 | -4.61% | 15 | Apr 22, 2025 | |
| PCVX Vaxcyte | Initiates: Overweight | n/a | $31.55 | - | 1 | Apr 22, 2025 | |
| MRK Merck & Co. | Initiates: Neutral | $85 | $82.71 | +2.77% | 11 | Apr 22, 2025 | |
| LLY Eli Lilly and Company | Initiates: Overweight | $975 | $660.49 | +47.62% | 12 | Apr 22, 2025 | |
| GILD Gilead Sciences | Assumes: Overweight | $125 | $120.14 | +4.05% | 15 | Apr 22, 2025 | |
| ABBV AbbVie | Initiates: Overweight | $210 | $201.47 | +4.23% | 15 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $160 → $165 | $131.62 | +25.36% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $18.05 | +10.80% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $190 → $180 | $135.19 | +33.15% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $100 | $78.24 | +27.81% | 1 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $3 | $2.02 | +48.51% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $1.26 | +138.10% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.43 | +529.37% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $36.88 | +157.59% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $14.72 | +35.87% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $70.90 | +2.96% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $2.18 | +450.46% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $1.97 | -23.86% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $2.25 | $0.45 | +398.34% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $221.49 | +71.57% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $85.85 | -4.48% | 5 | Jan 16, 2019 |
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Overweight
Price Target: $535 → $485
Current: $395.92
Upside: +22.50%
Amgen
Jun 24, 2025
Reiterates: Neutral
Price Target: $305
Current: $289.33
Upside: +5.42%
Bristol-Myers Squibb Company
Apr 23, 2025
Reiterates: Neutral
Price Target: $55
Current: $47.85
Upside: +14.94%
Regeneron Pharmaceuticals
Apr 22, 2025
Assumes: Overweight
Price Target: $695
Current: $561.55
Upside: +23.76%
Pfizer
Apr 22, 2025
Initiates: Neutral
Price Target: $24
Current: $25.16
Upside: -4.61%
Vaxcyte
Apr 22, 2025
Initiates: Overweight
Price Target: n/a
Current: $31.55
Upside: -
Merck & Co.
Apr 22, 2025
Initiates: Neutral
Price Target: $85
Current: $82.71
Upside: +2.77%
Eli Lilly and Company
Apr 22, 2025
Initiates: Overweight
Price Target: $975
Current: $660.49
Upside: +47.62%
Gilead Sciences
Apr 22, 2025
Assumes: Overweight
Price Target: $125
Current: $120.14
Upside: +4.05%
AbbVie
Apr 22, 2025
Initiates: Overweight
Price Target: $210
Current: $201.47
Upside: +4.23%
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $131.62
Upside: +25.36%
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $18.05
Upside: +10.80%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $135.19
Upside: +33.15%
Aug 29, 2024
Initiates: Overweight
Price Target: $100
Current: $78.24
Upside: +27.81%
Aug 14, 2024
Maintains: Overweight
Price Target: $10 → $3
Current: $2.02
Upside: +48.51%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $1.26
Upside: +138.10%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.43
Upside: +529.37%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $36.88
Upside: +157.59%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $14.72
Upside: +35.87%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $70.90
Upside: +2.96%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $2.18
Upside: +450.46%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $1.97
Upside: -23.86%
Aug 16, 2022
Maintains: Equal-Weight
Price Target: $2.5 → $2.25
Current: $0.45
Upside: +398.34%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $221.49
Upside: +71.57%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $85.85
Upside: -4.48%